Biomarin Pharmaceutical (BMRN) EBIT (2009 - 2026)

Biomarin Pharmaceutical has disclosed EBIT across 18 years of filings, most recently posting $129.6 million for Q1 2026.

• Quarterly EBIT fell 42.1% year-over-year to $129.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $315.2 million (down 49.13% YoY) and the FY2025 annual result came in at $409.5 million, down 15.43% from the prior year.
• EBIT improved to $129.6 million in Q1 2026, from -$44.6 million in the prior quarter.
• Over five years, EBIT peaked at $276.9 million in Q2 2025 and troughed at -$46.7 million in Q3 2025.
• A 5-year average of $80.6 million and a median of $65.6 million in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2023 — EBIT surged 1362.93% — and 2025, when it tumbled 141.0%.
• Tracing BMRN's EBIT over 5 years: stood at -$13.1 million in 2022, then jumped by 308.43% to $27.3 million in 2023, then jumped by 491.69% to $161.4 million in 2024, then slumped by 127.64% to -$44.6 million in 2025, then surged by 390.61% to $129.6 million in 2026.
• Business Quant data shows BMRN's EBIT at $129.6 million in Q1 2026, -$44.6 million in Q4 2025, and -$46.7 million in Q3 2025.